ダウンロード数: 168
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| s41598-017-09632-0.pdf | 1.29 MB | Adobe PDF | 見る/開く |
| タイトル: | A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| 著者: | Yamashiro, Kenji Mori, Keisuke Honda, Shigeru Kano, Mariko Yanagi, Yasuo Obana, Akira Sakurada, Yoichi Sato, Taku Nagai, Yoshimi Hikichi, Taiichi Kataoka, Yasushi Hara, Chikako Koyama, Yasurou Koizumi, Hideki Yoshikawa, Munemitsu Miyake, Masahiro   Nakata, Isao Tsuchihashi, Takashi Horie-Inoue, Kuniko Matsumiya, Wataru Ogasawara, Masashi Obata, Ryo Yoneyama, Seigo Matsumoto, Hidetaka Ohnaka, Masayuki Kitamei, Hirokuni Sayanagi, Kaori Ooto, Sotaro Tamura, Hiroshi  https://orcid.org/0000-0002-7740-2732 (unconfirmed)Oishi, Akio https://orcid.org/0000-0002-0977-9458 (unconfirmed)Kabasawa, Sho Ueyama, Kazuhiro Miki, Akiko Kondo, Naoshi Bessho, Hiroaki Saito, Masaaki Takahashi, Hidenori Tan, Xue Azuma, Keiko Kikushima, Wataru Mukai, Ryo Ohira, Akihiro Gomi, Fumi Miyata, Kazunori Takahashi, Kanji Kishi, Shoji Iijima, Hiroyuki Sekiryu, Tetsuju Iida, Tomohiro Awata, Takuya Inoue, Satoshi Yamada, Ryo https://orcid.org/0000-0002-1587-630X (unconfirmed)Matsuda, Fumihiko Tsujikawa, Akitaka Negi, Akira Yoneya, Shin Iwata, Takeshi Yoshimura, Nagahisa |
| 著者名の別形: | 山城, 健児 吉川, 宗光 三宅, 正裕 仲田, 勇夫 大音, 壮太郎 田村, 寛 大石, 明生 山田, 亮 松田, 文彦 辻川, 明孝 吉村, 長久 |
| キーワード: | Macular degeneration Retinal diseases |
| 発行日: | 23-Aug-2017 |
| 出版者: | Springer Nature |
| 誌名: | Scientific Reports |
| 巻: | 7 |
| 論文番号: | 9196 |
| 抄録: | We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8, 480, 849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of <5 × 10[−6] were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment. |
| 著作権等: | © The Author(s) 2017 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| URI: | http://hdl.handle.net/2433/231027 |
| DOI(出版社版): | 10.1038/s41598-017-09632-0 |
| PubMed ID: | 28835685 |
| 出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。